Home ›
Thyroid Cancer Trials ›
NCT05852223
Pembrolizumab in High-risk Thyroid Cancer
This window of opportunity trial is studying a checkpoint inhibitor agent to treat differentiated thyroid cancer in a neoadjuvant setting. A checkpoint inhibitor is a compound aimed at restoring tumor immunosurveillance. The name of this agent is pembrolizumab.
Trial Details
NCT ID NCT05852223
Phase PHASE2
Sponsor Istituti Clinici Scientifici Maugeri SpA
Status RECRUITING
Cancer Type Thyroid Cancer
Interventions
Locations (sample) Pavia, Lombardy, Italy|45.19205,9.15917
Key Eligibility Criteria
Male/female participants who are at least 18 years of age on the day of signing informed consent with histologically confirmed diagnosis of differe… Patients with a risk \> 20% for persistent/recurrent disease: primary tumor \> 4 cm; multifocal papillary microcarcinoma with extra tumor extension… Poorly differentiated carcinoma; Hurtle cell carcinoma. Patients with distant metastasis at diagnosis.
For full eligibility, visit ClinicalTrials.gov .
Check If You May Be Eligible
Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.
Find Thyroid Cancer Trials on Trialify →